SMI closes higher as Roche leads a 77-point gain

The SMI closed 77 points higher, or 0.5 percent, at 14,539 points on October 26, 2026, according to RTTNews. The advance followed easing inflation concerns and optimism about corporate earnings.

Roche was the main support, rising 1.4 percent after positive lung-cancer study data and a JPMorgan price-target increase, Moneycab reported. Novartis fell 0.4 percent ahead of its third-quarter results.

Why did the SMI rise on Monday?

The benchmark stayed positive for most of the session after a brief early dip. Roche's defensive weight and the improving earnings backdrop helped the index recover above 14,500 points. The SMI finished just below its 14,544-point session high, according to finanzen.ch.

SMI winners and losers on October 26

The following closing moves were published for the SMI constituents by finanzen.net:

• ABB up 2.8 percent.
• Sandoz up 2.1 percent.
• Roche up 1.4 percent: positive study data and a higher JPMorgan target.
• Sika down 2.2 percent: the company announced an acquisition and faced analyst repositioning.
• Givaudan down 1.3 percent.
• Novartis down 0.4 percent ahead of quarterly results.

Fourteen of the 20 SMI members rose and six declined. Technology and industrial shares also attempted a recovery after recent pressure, while Sika lagged.

What comes next for the SMI

• October 27, 2026, 8:00 a.m. ET: Novartis holds its third-quarter earnings conference call; analysts expect USD 14.53 billion in sales and USD 2.27 earnings per share, MarketBeat reports.

SMI price data for October 26, 2026

The SMI closed at 14,539 points on October 26, 2026, up 77 points or 0.5 percent versus the previous close of 14,462 points, RTTNews reported. It opened at 14,472 points and reached a high of 14,544 points.

More market reports and analysis on the SMI